Advertisement

Novel HPLC-Based Screening Method to Assess Developability of Antibody-Like Molecules

  • Neeraj Kohli
  • Melissa L. Geddie
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1575)

Abstract

The discovery of antibodies that bind to targets with high affinity is now a routine exercise. However, it is still challenging to screen for candidates that, in addition to having excellent biological properties, also have optimal biophysical characteristics. Here, we describe a simple HPLC-based screening method to assess for developability factors earlier in the discovery process.

Key words

Standup monolayer adsorption chromatography Developability Colloidal stability Zenix column Size exclusion chromatography 

References

  1. 1.
    Bradbury ARM, Sidhu S, Dübel S et al (2011) Beyond natural antibodies: the power of in vitro display technologies. Nat Biotechnol 29:245–254CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Buss NA, Henderson SJ, Mcfarlane M et al (2012) Monoclonal antibody therapeutics: history and future Introduction—a brief history of therapeutic monoclonal antibodies. Curr Opin Pharmacol 12:615–622CrossRefPubMedGoogle Scholar
  3. 3.
    von Mehren M, Adams GP, Weiner LM (2003) Monoclonal antibody therapy for cancer. Annu Rev Med 54:343–369CrossRefGoogle Scholar
  4. 4.
    Sliwkowski MX, Mellman IAntibody therapeutics in cancer. Science (New York, NY) 341:1192–1198Google Scholar
  5. 5.
    Buttmann M, Wiendl H (2010) Therapeutic monoclonal antibodies in clinical neurology. Nervenarzt 81:753–764 quiz 765–6CrossRefPubMedGoogle Scholar
  6. 6.
    Chan AC, Carter PJ (2010) Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 10:301–316CrossRefPubMedGoogle Scholar
  7. 7.
    Chao G, Lau WL, Hackel BJ et al (2006) Isolating and engineering human antibodies using yeast surface display. Nat Protoc 1:755–768CrossRefPubMedGoogle Scholar
  8. 8.
    Lee EC, Owen M (2012) The application of transgenic mice for therapeutic antibody discovery. Methods Mol Biol 901:137–148CrossRefPubMedGoogle Scholar
  9. 9.
    Tiller T (2011) Single B cell antibody technologies. N Biotechnol 28(5):453–457CrossRefPubMedGoogle Scholar
  10. 10.
    Bratkovič T (2010) Progress in phage display: evolution of the technique and its applications. Cell Mol Life Sci 67(5):749–767CrossRefPubMedGoogle Scholar
  11. 11.
    Xu L, Kohli N, Rennard R et al (2013) Rapid optimization and prototyping for therapeutic antibody-like molecules. MAbs 5:237–254CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Schaffitzel C, Hanes J, Jermutus L et al (1999) Ribosome display: an in vitro method for selection and evolution of antibodies from libraries. J Immunol Methods 231:119–135CrossRefPubMedGoogle Scholar
  13. 13.
    Jarasch A, Koll H, Regula JT et al (2015) Developability assessment during the selection of novel therapeutic antibodies. J Pharm Sci 104(6):1885–1898CrossRefPubMedGoogle Scholar
  14. 14.
    Yang X, Xu W, Dukleska S et al (2013) Developability studies before initiation of process development: improving manufacturability of monoclonal antibodies. MAbs 5:787–794CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Saxena V, Panicucci R, Joshi Y et al (2009) Developability assessment in pharmaceutical industry: an integrated group approach for selecting developable candidates. J Pharm Sci 98(6):1962–1979CrossRefPubMedGoogle Scholar
  16. 16.
    Shih HH (2012) Discover process for antibody-based therapeutics. In: Tabrizi MA, Bornstein GG, Klakamp SL (eds) Development of antibody-based therapeutics. Springer, New York, NYGoogle Scholar
  17. 17.
    Lauer TM, Agrawal NJ, Chennamsetty N et al (2012) Developability index: a rapid in silico tool for the screening of antibody aggregation propensity. J Pharm Sci 101:102–115CrossRefPubMedGoogle Scholar
  18. 18.
    Liu Y, Caffry I, Wu J et al (2014) High-throughput screening for developability during early-stage antibody discovery using self-interaction nanoparticle spectroscopy. MAbs 6:483–492CrossRefPubMedGoogle Scholar
  19. 19.
    Jacobs SA, Wu SJ, Feng Y et al (2010) Cross-interaction chromatography: a rapid method to identify highly soluble monoclonal antibody candidates. Pharm Res 27:65–71CrossRefPubMedGoogle Scholar
  20. 20.
    Hotzel I, Theil FP, Bernstein LJ et al (2012) A strategy for risk mitigation of antibodies with fast clearance. MAbs 4:753–760CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Blessy M, Patel RD, Prajapati PN et al (2014) Development of forced degradation and stability indicating studies of drugs—a review. J Pharm Anal 4(3):159–165CrossRefGoogle Scholar
  22. 22.
    Hawe A, Wiggenhorn M, van de Weert M et al (2012) Forced degradation of therapeutic proteins. J Pharm Sci 101(3):895–913CrossRefPubMedGoogle Scholar
  23. 23.
    Lavinder JJ, Hari SB, Sullivan BJ et al (2009) High-throughput thermal scanning: a general, rapid dye-binding thermal shift screen for protein engineering. J Am Chem Soc 131:3794–3795CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Kohli N, Jain N, Geddie ML et al (2015) A novel screening method to assess developability of antibody-like molecules. MAbs 0862:37–41Google Scholar

Copyright information

© Springer Science+Business Media LLC 2017

Authors and Affiliations

  1. 1.Merrimack Pharmaceuticals, Inc.CambridgeUSA

Personalised recommendations